Header Logo

Connection

Ajaypal Singh to Anemia

Back to Details
This is a "connection" page, showing publications Ajaypal Singh has written about Anemia.
Ajaypal Singh
Connection Strength
15.877
Anemia
  1. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023; 54(1-2):1-13.
    View in: PubMed
    Score: 0.763
  2. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
    View in: PubMed
    Score: 0.747
  3. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
    View in: PubMed
    Score: 0.727
  4. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
    View in: PubMed
    Score: 0.722
  5. Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO. Am J Nephrol. 2022; 53(5):361-365.
    View in: PubMed
    Score: 0.722
  6. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
    View in: PubMed
    Score: 0.699
  7. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
    View in: PubMed
    Score: 0.699
  8. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. Curr Opin Nephrol Hypertens. 2019 11; 28(6):600-606.
    View in: PubMed
    Score: 0.608
  9. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8.
    View in: PubMed
    Score: 0.372
  10. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4.
    View in: PubMed
    Score: 0.322
  11. Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6.
    View in: PubMed
    Score: 0.320
  12. The etiology of anemia in heart failure. Preface. Heart Fail Clin. 2010 Jul; 6(3):xvii-xviii.
    View in: PubMed
    Score: 0.318
  13. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32.
    View in: PubMed
    Score: 0.318
  14. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4.
    View in: PubMed
    Score: 0.316
  15. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6.
    View in: PubMed
    Score: 0.313
  16. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
    View in: PubMed
    Score: 0.311
  17. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6.
    View in: PubMed
    Score: 0.307
  18. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46.
    View in: PubMed
    Score: 0.304
  19. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41.
    View in: PubMed
    Score: 0.297
  20. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13.
    View in: PubMed
    Score: 0.285
  21. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50.
    View in: PubMed
    Score: 0.284
  22. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
    View in: PubMed
    Score: 0.282
  23. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8.
    View in: PubMed
    Score: 0.277
  24. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90.
    View in: PubMed
    Score: 0.276
  25. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83.
    View in: PubMed
    Score: 0.271
  26. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008 Jan-Feb; 21(1):1-6.
    View in: PubMed
    Score: 0.268
  27. Anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jan; 3(1):3-6.
    View in: PubMed
    Score: 0.267
  28. Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol. 2007 Dec; 3(12):638-9.
    View in: PubMed
    Score: 0.264
  29. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
    View in: PubMed
    Score: 0.263
  30. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7.
    View in: PubMed
    Score: 0.258
  31. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9.
    View in: PubMed
    Score: 0.256
  32. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9.
    View in: PubMed
    Score: 0.256
  33. Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant. 2007 Jul; 22(7):1806-10.
    View in: PubMed
    Score: 0.255
  34. The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30.
    View in: PubMed
    Score: 0.248
  35. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98.
    View in: PubMed
    Score: 0.248
  36. Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. Med Clin North Am. 2005 May; 89(3):549-61.
    View in: PubMed
    Score: 0.223
  37. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8.
    View in: PubMed
    Score: 0.220
  38. Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485.
    View in: PubMed
    Score: 0.189
  39. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
    View in: PubMed
    Score: 0.184
  40. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.
    View in: PubMed
    Score: 0.143
  41. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497.
    View in: PubMed
    Score: 0.133
  42. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
    View in: PubMed
    Score: 0.132
  43. Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J. 2013 Aug; 34(8):814-8.
    View in: PubMed
    Score: 0.099
  44. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58.
    View in: PubMed
    Score: 0.097
  45. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46.
    View in: PubMed
    Score: 0.094
  46. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401.
    View in: PubMed
    Score: 0.090
  47. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61.
    View in: PubMed
    Score: 0.090
  48. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.088
  49. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55.
    View in: PubMed
    Score: 0.081
  50. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32.
    View in: PubMed
    Score: 0.076
  51. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510.
    View in: PubMed
    Score: 0.075
  52. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009 Aug; 76(4):376-82.
    View in: PubMed
    Score: 0.074
  53. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69.
    View in: PubMed
    Score: 0.074
  54. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 Mar; 24(3):431-4.
    View in: PubMed
    Score: 0.069
  55. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9.
    View in: PubMed
    Score: 0.067
  56. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84.
    View in: PubMed
    Score: 0.063
  57. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005; 6 Suppl 3:S35-41.
    View in: PubMed
    Score: 0.054
  58. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.